Vanesa-Sindi Ivanova

A dynamic and proactive PhD candidate in Oncology, Pathology and Genetics at

University Hospital Basel, with a solid background in Cardiovascular Science. Proficient in

fostering long-term collaborative partnerships and showcasing exceptional communication

abilities. Skilled in leadership and teamwork, with meticulous attention to detail.

Presents innovative problem-solving skills, and adeptly navigates high-pressure situations,

meeting stringent deadlines. Driven by a commitment to deliver cutting-edge

solutions in healthcare. Passionate about addressing the unmet needs of diverse patients

and communities. Eager to utilise research expertise to make substantial contributions,

steering groundbreaking scientific initiatives to fruition.

Certifications:

• Pharmaceutical Regulatory Affairs by Strategic Axis Training Academy – to be completed in July

• Health Care Strategy by Harvard Business School (HBS) Online

• The FDA and Prescription Drugs: Current Controversies in Context by Harvard University edX

• Public Health Ethics

• Good scientific conduct in health sciences

• Preparing and Holding Presentations Effectively in the Natural and Life Sciences

Research (PhD), University Hospital Basel

IVD experience:

• Working on validation and implementation of custom HTS lymphoma panel for diagnostic use
• Applying a custom TP53 HTS panel in relapsed/refractory mantle cell lymphoma patients

Clinical project experience, working along R&D scientists, HCPs and KOLs:

• Characterising primary bone diffuse large B-cell lymphoma (PB-DLBCL) as a distinct extranodal
• lymphoma
• Molecular characterization and genetic subclassification of diffuse large B-cell lymphoma (DLBCL)
• Profiling the mutational landscape of primary breast marginal zone lymphoma
• Characterising post-transplant lymphoproliferative disease patients on molecular and genomic levels

Research (MRes), Institute for Biomedical Research, Department of Cardiovascular Science, University of Birmingham

• Confidential project working within a cross-functional team : Investigating the effect of selective Btk inhibition on platelet activation and signalling, collaborating with clinical investigators
• Working with biologics, handling data analysis and interpretation, performing a meta-analysis on clinical trials involving Btk inhibitors

Ambassador, Projects Abroad

• Representing Projects Abroad at various events, advertising, giving talks and presentations on the work done and opportunities provided by the company

Research (BSc), Institute for Biomedical Research, Department of Cardiovascular Science, University of Birmingham

• Looking at the interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ in murine platelet regulation

Laboratory Technician, Institute of Biomedical Sciences, Department of Cardiovascular Science, University of Birmingham

• Adherence to SOPs, regulations and code of practice, as well as writing study protocols

Volunteer, Hospital Pediátrico del Niño Jesús

• Having interactions with HCPs, attended consultant discussions, assisted in carrying out check-ups, and took patients' history

Intern, Department of Haematology, Queen Elizabeth Hospital

• Attended consultant discussion meetings
• Exposure to diagnostics and medical SOPs by experiencing diagnostic processes and the selection of appropriate treatment protocols; experience with prescribers and patient care

Intern, Birmingham & Midland Eye Centre

• Acquired organisational skills to effectively manage a large and complex caseload when involved in outpatient procedures and A&E
• Acquired a detailed understanding of best practices

Publications:

In Histopathology: "Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis"

In Pathobiology: "Molecular characterization and genetic subclassification comparison of diffuse large B-cell lymphoma (DLBCL) real-life experience with 74 cases"

In eClinicalMedicine: "Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase ½ trial of the European MCL network (SAKK 36/13)"

In Blood: "Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice"

Courses and certifications:

• Pharmaceutical Regulatory Affairs by Strategic Axis Training Academy – to be completed in July
• Certification in Health Care Strategy by Harvard Business School (HBS) Online
• The FDA and Prescription Drugs: Current Controversies in Context by Harvard University edX
• Public Health Ethics
• Good scientific conduct in health sciences
• Preparing and Holding Presentations Effectively in the Natural and Life Sciences